• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.老年淋巴瘤患者的大剂量化疗与自体干细胞移植
Curr Oncol Rep. 2015 Sep;17(9):42. doi: 10.1007/s11912-015-0465-x.
2
A Review of Autologous Stem Cell Transplantation in Lymphoma.淋巴瘤自体干细胞移植综述
Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1.
3
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.大剂量噻替派为基础的化疗联合自体造血干细胞支持治疗老年原发性中枢神经系统淋巴瘤：一项欧洲回顾性研究。
Bone Marrow Transplant. 2017 Aug;52(8):1113-1119. doi: 10.1038/bmt.2017.23. Epub 2017 Apr 24.
4
[Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].[自体造血干细胞移植治疗侵袭性B细胞非霍奇金淋巴瘤]
Gan To Kagaku Ryoho. 2005 Dec;32(13):2059-64.
5
Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma.淋巴瘤患者自体干细胞移植后危及生命并发症的临床特征
Leuk Lymphoma. 2015;56(11):3090-5. doi: 10.3109/10428194.2015.1034700. Epub 2015 May 12.
6
Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation.大剂量化疗联合自体造血干细胞移植治疗淋巴瘤后幸存者的治疗后工作模式。
BMC Cancer. 2021 Feb 8;21(1):143. doi: 10.1186/s12885-021-07836-2.
7
Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.60 岁及以下未经治疗的高危弥漫性大 B 细胞淋巴瘤患者的 upfront 自体干细胞移植。
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):404-9. doi: 10.1016/j.clml.2013.03.003. Epub 2013 Jun 10.
8
High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.高剂量化疗及自体干细胞移植治疗外周T细胞淋巴瘤：移植时达到完全缓解可预测生存情况。
Ann Hematol. 2007 Jun;86(6):435-42. doi: 10.1007/s00277-007-0254-1. Epub 2007 Jan 26.
9
High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis.大剂量化疗后自体干细胞移植作为侵袭性非霍奇金淋巴瘤的一线治疗：一项荟萃分析。
Haematologica. 2003 Nov;88(11):1304-15.
10
High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation.西半球患者结外NK/T淋巴瘤的大剂量治疗及自体干细胞移植：欧洲血液与骨髓移植学会的一项研究
Leuk Lymphoma. 2015;56(12):3295-300. doi: 10.3109/10428194.2015.1037764. Epub 2015 Aug 26.

引用本文的文献

1
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma.CAR T 细胞治疗后接受 loncastuximab tesirine 治疗的复发或难治性弥漫性大 B 细胞淋巴瘤患者的结局。
Blood Cancer J. 2024 Nov 28;14(1):210. doi: 10.1038/s41408-024-01195-4.
2
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.对于 2 线或多线既往治疗后复发或难治性大 B 细胞淋巴瘤的老年患者和/或 ECOG 体能状态较差的患者，与化疗免疫治疗相比，axicabtagene ciloleucel 的获益。
Am J Hematol. 2024 May;99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024 Mar 19.
3
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.阿基仑赛注射液对比标准治疗用于 65 岁及以上复发/难治性大 B 细胞淋巴瘤患者的安全性和有效性。
Clin Cancer Res. 2023 May 15;29(10):1894-1905. doi: 10.1158/1078-0432.CCR-22-3136.
4
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China.自体造血干细胞移植对一线和复发原发性中枢神经系统淋巴瘤的影响：中国的一项回顾性研究。
Ann Transplant. 2023 Jan 3;28:e938467. doi: 10.12659/AOT.938467.
5
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.一项造血细胞移植项目在四年期间的实际情况概述，包括前瞻性登记、排除原因及最终供体选择。
Bone Marrow Transplant. 2022 Feb;57(2):176-182. doi: 10.1038/s41409-021-01506-4. Epub 2021 Oct 28.
6
Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.基因工程细胞治疗时代淋巴瘤的造血细胞移植：现在还不是彻底抛弃旧车换新车的时候。
Curr Opin Hematol. 2019 Jul;26(4):288-293. doi: 10.1097/MOH.0000000000000515.
7
Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature.原发性中枢神经系统淋巴瘤的造血干细胞移植：文献综述
Int J Hematol. 2019 Mar;109(3):260-277. doi: 10.1007/s12185-019-02594-1. Epub 2019 Jan 22.

本文引用的文献

1
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.卡莫司汀、依托泊苷、阿糖胞苷和马法兰大剂量化疗后进行自体干细胞移植，是治疗预后不良的老年淋巴瘤患者的有效方法。
Leuk Lymphoma. 2015;56(8):2379-87. doi: 10.3109/10428194.2014.1001987. Epub 2015 Feb 20.
2
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.老年非霍奇金淋巴瘤患者接受大剂量治疗及自体干细胞移植的良好预后。
Biol Blood Marrow Transplant. 2014 Dec;20(12):2004-9. doi: 10.1016/j.bbmt.2014.08.019. Epub 2014 Aug 28.
3
R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.对于老年套细胞淋巴瘤患者，采用R-CHOP方案或R-HyperCVAD方案，联合或不联合自体干细胞移植进行治疗。
Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):92-7. doi: 10.1016/j.clml.2014.07.017. Epub 2014 Aug 1.
4
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.共病年龄指数：异基因造血细胞移植前生物学年龄的一种临床测量方法。
J Clin Oncol. 2014 Oct 10;32(29):3249-56. doi: 10.1200/JCO.2013.53.8157. Epub 2014 Aug 25.
5
Hematopoietic stem cell aging.造血干细胞衰老。
Curr Opin Immunol. 2014 Aug;29:86-92. doi: 10.1016/j.coi.2014.05.002. Epub 2014 Jun 3.
6
Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation.衰老会损害自体干细胞移植后的长期造血再生。
Biol Blood Marrow Transplant. 2014 Jun;20(6):865-71. doi: 10.1016/j.bbmt.2014.03.001. Epub 2014 Mar 7.
7
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.对于年龄≥60岁的B细胞淋巴瘤成年患者，采用递增剂量氟达拉滨联合大剂量I-131-托西莫单抗及自体造血干细胞移植治疗。
Biol Blood Marrow Transplant. 2014 Jun;20(6):770-5. doi: 10.1016/j.bbmt.2014.02.004. Epub 2014 Feb 12.
8
High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.老年复发/难治性弥漫性大B细胞淋巴瘤患者的大剂量化疗联合自体干细胞移植：一项全国性回顾性研究
Biol Blood Marrow Transplant. 2014 May;20(5):684-9. doi: 10.1016/j.bbmt.2014.01.025. Epub 2014 Jan 31.
9
Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.老年血液系统恶性肿瘤的造血干细胞移植：移植临床中的老年医学原则。
J Natl Compr Canc Netw. 2014 Jan;12(1):128-36. doi: 10.6004/jnccn.2014.0010.
10
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.在利妥昔单抗时代治疗弥漫性大 B 细胞淋巴瘤患者的改良国际预后指数（NCCN-IPI）。
Blood. 2014 Feb 6;123(6):837-42. doi: 10.1182/blood-2013-09-524108. Epub 2013 Nov 21.

老年淋巴瘤患者的大剂量化疗与自体干细胞移植

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.

作者信息

Lahoud Oscar B, Sauter Craig S, Hamlin Paul A, Dahi Parastoo Bahrami

机构信息

Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Curr Oncol Rep. 2015 Sep;17(9):42. doi: 10.1007/s11912-015-0465-x.

DOI:10.1007/s11912-015-0465-x
PMID:26201264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5542393/
Abstract

High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HDT/ASCT) can improve survival in patients with lymphoma. Limited experience is available on the safety and efficacy of HDT/ASCT in elderly patients. In this article, we review the published data on the role of HDT/ASCT in management of lymphoma in older patients. Based on available data, evaluation of comorbidities, functional status, and comprehensive geriatric assessment (CGA) will help identify those who can benefit most from this intervention. Prospective clinical trials focusing on HDT/ASCT in older patients with lymphoma are needed to establish optimal management protocols in this select population.

摘要

大剂量化疗后行自体造血干细胞移植（HDT/ASCT）可提高淋巴瘤患者的生存率。关于HDT/ASCT在老年患者中的安全性和有效性的经验有限。在本文中，我们回顾了已发表的关于HDT/ASCT在老年淋巴瘤患者治疗中作用的数据。根据现有数据，评估合并症、功能状态和综合老年评估（CGA）将有助于确定那些能从该干预措施中获益最大的患者。需要开展针对老年淋巴瘤患者HDT/ASCT的前瞻性临床试验，以制定这一特定人群的最佳治疗方案。